|
|
 |
|
Viewing report
|
|
|
|
Anti-hypertensives: Patent Defense Strategies - Combating Generic Competition Through Lifecycle Management
Datamonitor, Jan 2001
It is evident that patents provide an incentive for pharmaceutical companies to invest in research and development (R&D), since they enable companies to recoup the money spent during the development and launch of a new product. However, once patents expire, generic competition tends to result in a dramatic decline in the sales of the branded product and, therefore, companies are developing increasingly sophisticated strategies for defending and competing against generic competition. This brief will focus on the effect of patent expiries, both past and future, on the anti-hypertensives market since this is the largest pharmaceutical market in terms of value and constitutes a crucial component of the portfolio of the leading cardiovascular companies. However, although the brief concentrates on the anti-hypertensives market, which is already highly genericized and currently facing another major round of patent expiries, many of the principles outlined can be applied to other markets.
Customers who bought this item also bought
Generics Defense Strategies: Effective Brand Protection through Patent, Formulation, OTC and DTC Strategies
Lifecycle Management Strategies: Maximizing ROI through Indication Expansion, Reformulation and Rx-to-OTC Switching
Market Dynamics: HIV - Combating a Market Slowdown
Injectable Generic Drugs: Prospects and Opportunities to 2010
US and European Prescription Generic Markets: An Examination of Commercial and Regulatory Contrasts
The Blockbuster Drugs Outlook: Optimum management strategies throughout the product lifecycle
Patent Protection Strategies: Maximizing Market Exclusivity
The Latin American Market for Generic Drugs - A Comparative Study of 7 Key Markets
|
|
|
|
